Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)Peter Thuss‐Patience, Peter Reichardt, Kirstin Breithaupt et al.|European Journal of Cancer|2011Cited by 615
Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)Peter Thuss‐Patience, B. Gahn, S Daum et al.|Annals of Oncology|2012Cited by 70
Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)Peter Thuss‐Patience, Peter Reichardt, Albrecht Kretzschmar et al.|Journal of Clinical Oncology|2009Cited by 68
Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohortsPeter Thuss‐Patience, Peter Reichardt, Albrecht Kretzschmar et al.|British Journal of Cancer|2011Cited by 23
6504 Survial advantage for irinotecan versus best supportive care (BSC) as 2nd-line chemotherapy in gastric cancer – a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)P. Thuss-Patience, Peter Reichardt, Albrecht Kretzschmar et al.|European Journal of Cancer Supplements|2009Cited by 9